baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Call 820 REGN 17.05.202.../ DE000JB1SPV1 /

5/13/2024 10:23:41 AM	Chg.+0.02	Bid4:10:01 PM	Ask4:10:01 PM	Underlying	Strike price	Expiration date	Option type
1.43EUR	+1.42%	1.48 Bid Size: 10,000	- Ask Size: -	Regeneron Pharmaceut...	820.00 USD	5/17/2024	Call

GlobeNewswire 7:00 AM Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 5/10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 5/9 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 5/8 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 5/7 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 5/6 Regeneron Announces Investor Conference Presentations

GlobeNewswire 5/2 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 4/29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 4/26 Medigene AG reports Financial Results and Business Update for Q1 2024

GlobeNewswire 4/25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 4/24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 4/23 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 4/22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 4/18 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...

GlobeNewswire 4/18 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...

GlobeNewswire 4/16 Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire 4/16 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 4/15 Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation

GlobeNewswire 4/11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...

GlobeNewswire 4/9 Opthea Appoints John Han, PharmD, as VP Medical Affairs

GlobeNewswire 4/7 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...

GlobeNewswire 4/1 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...

GlobeNewswire 3/25 Regeneron Provides Update on Biologics License Application for Odronextamab

GlobeNewswire 3/22 Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm

GlobeNewswire 3/20 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

JP Morgan Call 820 REGN 17.05.202.../ DE000JB1SPV1 /

If you wish to receive reply to your feedback, please provide your email address.